SmallCapVoice.com, Inc.

VCI Global is a diversified holding company. Through its subsidiaries, it focuses on consulting, fintech, AI, robotics, and cybersecurity. Based in Kuala Lumpur, Malaysia, our main operations are centered in Asia, with significant visibility across Asia Pacific, the United States, Europe, and the Middle East. VCIG primarily offers consulting services in capital markets, real estate, AI, and technology. In technology businesses, the company operates a proprietary financing platform that serves companies and individuals, as well as a secured messaging platform serving governments and organizations. We also invest, incubate, accelerate, and commercialize businesses and technologies in AI and robotics.

Brian Foote, CEO of HUMBL, individually shares his perspectives on recent developments and the Company's ongoing business operations. Moreover, he will deliver a Q&A of top questions raised by shareholders to the Company's new investor relations firm SmallCapVoice.com, underscoring the Company's commitment to transparent communication and engagement with its investor community. “We are deeply focused on the HUMBL Wallet for private and public sector clients and are underway on work in both segments in areas such as sports leagues and municipal government. We look forward to sharing routine progress and investor relations updates with our HUMBL Community via SmallCapVoice.com,” said Brian Foote, CEO of HUMBL. “We're pleased to begin these quarterly shareholder Q&A updates to do so.”

Cliff Emmons, CEO of IIOT-OXYS, Inc. (Oxys) stated, "We're pleased to announce the first half year of revenue in 2023 was a significant improvement over the same period in 2022 (an increase of 376%) and sustained the revenue momentum achieved throughout 2022. We expect this momentum achieved in the first half of 2023 will continue through the remainder of 2023 - given adequate funding to fuel sales & marketing efforts. Our leadership team also managed costs well, lowering operating expenses by 24%. Our strong six months revenue and our confidence this momentum will continue through 2023, and beyond, are based on the following factors: Our current DOT Bridge Monitoring Contract and overall Structural Health Monitoring ("SHM") vertical is the foundation of our revenue momentum. The current monitoring revenue will continue through the second half of 2023, with the previously approved expansion to continue beyond June. We believe our discussions with our main contractor to the DOT for extensions and expansions have been favorable. We also believe that prospects with our current DOT state, and DOT contacts in two other northeast states bode well for future business in mid-2024. There is still potential for local municipalities in our current northeast state to contribute revenue in the second half of 2023 and into 2024. Our Smart Manufacturing vertical is benefiting from the progress on our CNC Proof of Concept ("POC"), that successfully concluded in May 2023, and has resulted in a signed Software-as-a-Service ("SaaS") contract in June 2023. Public endorsements and promotional videos have begun and more are forthcoming featuring our Smart Manufacturing customer, Precision Metal Products Inc. We believe these endorsements and promotional videos will lead to other paid CNC POCs and additional SaaS contracts, which would contribute to revenue in the second half of 2023 and beyond. It is expected these endorsements will also strengthen our position to secure additional POCs for other discrete manufacturing processes, including metal stamping, plastic injection molding, plastic extrusion, and automated assembly and test. Our Strategic Partnership development continues to be a "force multiplier" for us. The strength of our Aingura IIoT, S.L. partnership provides supplemental expertise, equipment and software, which ensures we continue to bring value to our customers. We will also continue to develop some of our other previously announced partnerships. We believe that our business development in these industries has high potential for success, due to the strength of their size and growth. The global smart manufacturing (also known as Industry 4.0) was $97.6 billion in 2022 and will reach $228.3 billion by 2027 (CAGR 18.5%),1 and the worldwide SHM industry was $2.0 billion in 2021 and will reach $4.0 billion by 2027 (CAGR of 14.6%).2 Among our many tailwinds, we do some headwinds. First, we have decided to discontinue our efforts with Aretas Sensor Networks ("Aretas") in the Indoor Air Quality ("IAQ") vertical and re-direct those resources to our better performing verticals. The second significant headwind is, since February, we have been unable to raise funds for ongoing operations through our existing financing agreements due to market conditions. Our CEO and COO have not received any compensation since mid-April (their salaries have accrued), and the lack of funds have significantly limited sales and marketing efforts. Our management is working to secure funding from our lead investor to pay for ongoing expenses and the leadership team is considering many options for both the short and long term. These options will depend largely upon our ability to continue to raise funds and implement a marketing and sales plan. In the event we are unable to raise adequate funds, management may need to consider other options such as pursuing suitable companies to merge with or acquire us. Overall,

SmallCapVoice.com Inc, is thrilled to announce the availability of an exclusive interview featuring Tim Fernback, the CEO of Grid Battery Metals (TSXV: CELL) (OTCQB: EVKRF) (FRA: NMK2), as he delves into the exciting prospects of nickel and lithium in the rapidly expanding electric vehicle (EV) and battery sectors. Grid Battery Metals, a pioneering company, is strategically positioned in the battery metals market, with a strong focus on nickel and lithium. As the demand for EVs and battery technologies soars, both nickel and lithium are projected to experience significant growth over the next decade. In the insightful interview, Tim Fernback share how as the world transitions towards sustainable energy solutions, the demand for electric vehicles and energy storage systems is escalating. Nickel and lithium play crucial roles in advancing these technologies, and Grid Battery Metals is capitalizing on this opportunity by concentrating its efforts on these two essential battery metals. Tim then goes on to explain the connection between Grid Battery Metals and their partner, Surge Battery Metals (TSXV:NILI)(OTC PINK:NILIF)(FRA:DJ5C). Under Tim Fernback's visionary leadership, Grid Battery Metals has established itself as a leading player in the battery metals market. By honing in on nickel and lithium, the company is poised to meet the burgeoning demand for these metals, which are essential for the future of the EV and battery industries, through their 4 projects; Texas Spring, Clayton Valley, Grid Nickel, and Volt Canyon. The 2 nickel projects are located near FPX. Grid Nickel is of extra special interest, and Tim goes on to explain the abundance of awaruite, which is a naturally occurring nickel-iron alloy important in the manufacturing of environmentally efficient batteries for the electric vehicle markets globally. Tim continues to discuss company goals, including the recent shareholder update released by the company. The update included key highlights like a nickel project in British Columbia completing and the beginning of a lithium project at the Texas Spring and the Volt Canyon projects, both located in Nevada. Among other stated goals, Tim concludes by stating the company hopes to be ready for the 2024 drilling season. The interview concludes discussing the companies balance sheets and sustainability in the current economic state of both the US and Canada. “We're really well funded,” Tim states, “we just completed two financings for the company and we have over $4.5 million in just cash related working capital on our balance sheet.” Tim goes on to explain the additional capital on hand from the sale of property to Surge Battery Metals.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage immunotherapy company driven to fight cancer and improve patients' lives, announces that it has received approval from FDA on its pivotal registrational study design for Bria-IMT™ in combination with a checkpoint inhibitor in advanced metastatic breast cancer. FDA has approved the study design, the primary and secondary endpoints, and patient population in BriaCell's upcoming pivotal registration clinical study. The study will include advanced metastatic breast cancer patients who have exhausted all other treatment options. BriaCell is a clinical stage immunotherapy company developing novel treatments that boost the ability of the body's own cancer fighting cells to destroy cancer. More information is available at https://briacell.com/.

The Leadership of Luminar Media Group, Inc. Discuss the Business Plan and Science Behind Their Ultra-Premium, Top-Shelf Vodka in Audio Interview with SmallCapVoice.com Royale de Monte Carlo, headquartered in Miami, Florida, is an ultra-premium, icy cool, and deliciously smooth vodka sure to give long-lasting euphoric pleasure to any palate it graces. Created and produced by fifth generation master distillers located in the heart of the world-famous Cognac region of France, Royale de Monte Carlo was voted as the "World's Most Prestigious Vodka". https://royaledemontecarlo.com/ Experience the joy of royalty with every sip of Royale de Monte Carlo, and relish in its remarkable tasting notes. Boasting a pure, odorless profile with a refined, exotic finish, this transcendent vodka offers subtle hints of corduroy, cognac barrel, and slate, with undertones of grain mash and husk. Its silky-smooth texture, enhanced by nanotechnology, exudes a sweet, moderately grainy taste, culminating in a dry, intense finale featuring magnificent notes of champagne.

Nightfood CEO Sean Folkson provides updates on hotel distribution, recently initiated hotel and airline tests of Nightfood cookies as amenities, and answer investor questions. Nightfood is pioneering the category of sleep-friendly nighttime snacks. Over 80% of Americans snack regularly at night, resulting in an estimated 700 million nighttime snack occasions weekly, and an annual spend on night snacks of over $50 billion. The most popular choices are ice cream, cookies, chips, and candy. Recent research confirms such snacks, in addition to being generally unhealthy, can impair sleep, partly due to excess fat, sugar, and calories consumed before bed. Nightfood's sleep-friendly snacks are formulated by sleep and nutrition experts to contain less of those sleep-disruptive ingredients, along with a focus on ingredients and nutrients that research suggests can support nighttime relaxation and better sleep quality. The brand is focused on establishing widespread national distribution of Nightfood ice cream, cookies, and other snack formats in the high-margin hotel vertical. In March, 2023, Nightfood announced Sonesta International Hotels Corporation, the 8th largest hotel company in the United States, launched Nightfood ice cream into multiple Sonesta chains. Also in March, the Company announced its status as a Qualified Vendor of Choice Hotels, one of the world's largest lodging franchisors. Nightfood ice cream pints can be found in select locations of chains such as Sonesta, Courtyard by Marriott, Holiday Inn Express, Springhill Suites, Hyatt Place, Fairfield Inn & Suites and many more. Hotels are increasingly focused on supporting guest wellness, and one way to do that is by offering healthier and sleep-friendly snacks in their grab-and-go lobby shops. With an estimated 56,000 hotels across the United States, expanding distribution into a significant number of those hotels is expected to lead to profitability, consumer adoption of the nighttime snack category, and a strategically defensible position from which category leadership can be maintained. Questions can be directed to investors@Nightfood.com By signing up at ir.nightfood.com, investors can receive updates of filings and news releases in their inbox.

SmallCapVoice.com Inc. (“SCV”) announces the availability of an interview with Bruce Rintoul, a key member of the SusGlobal Energy Corp. (OTCQB: SNRG) ("SusGlobal" or the "Company")Board of Directors, to discuss his work with the environmental, agricultural and industrial biotechnology company. SusGlobal Energy Corp., the developer of SusGro™, an award winning and revolutionary pathogen free organic liquid fertilizer, is an environmental, agricultural and industrial biotechnology company focused on acquiring, developing, and monetizing a portfolio of proprietary technologies in the waste to energy and regenerative product applications globally. It is management's objective to grow SusGlobal into a significant sustainable waste to energy and regenerative products provider and a trusted brand for the fertilizer, soil and aquaculture market, as LEADERS IN THE CIRCULAR ECONOMY®. For more information, please visit the SusGlobal website, Twitter and Facebook pages.

Cliff Emmons, CEO of IIOT-OXYS, Inc. (Oxys) stated, "We're pleased to announce, as promised, 2022 revenue exceeded 2021, doing so by more than seven-fold. This is the highest annual revenue since the negative impacts of the COVID pandemic. Also, as promised, revenue in the second half of 2022 exceeded that in the first half. Furthermore, fourth quarter revenue exceeded third quarter revenue, marking three consecutive quarters of increasing revenue. Our leadership team also managed costs well, lowering operating expenses by 17%, and professional expenses were reduced by 47%. There were several factors that led to this strong growth in 2022, including the following: Our Department of Transportation (DOT) Bridge Monitoring contract: We were awarded a six-figure sub-contract from a major northeast state's DOT for bridge monitoring, in addition to the extension that was given on the previous contract. This project will continue to contribute a strong revenue stream through mid-2023, and we're confident our performance will yield further extensions and expansions in the second half of the year. Our continued focus on our Smart Manufacturing vertical enabled us to secure a CNC Proof of Concept (POC) contract in December 2022. The POC successfully kicked off in January 2023, is concluding next month, and is already yielding results that are impressing our customer. We expect a Software-as-a-Service (SaaS) contract to follow which we expect to contribute to revenue by the second half of 2023. The ongoing strength of our strategic partnership with Aingura IIoT, S.L., which provides supplemental expertise, equipment and software, ensuring we continue to bring value to our customers. Our partnership with a Canadian Indoor Air Quality Sensor and IIoT Platform company continues to progress well, and our retail sales efforts are beginning to show results. Looking forward through 2023 and beyond, and as previously stated, we believe this is a transition year from "surviving" to "thriving". It is anticipated that 2023 YoY revenue growth will meet or exceed that of 2022. This will be accomplished through our partnerships, successful pilots, experienced leadership, and savvy technological talent. These capabilities will allow us to leverage our high potential growth markets: the global smart manufacturing (also known as Industry 4.0) was $97.6 B USD in 2022 and will reach $228.3 B USD by 2027 (CAGR 18.5%);[1] the worldwide Structural Health Monitoring (SHM) industry was $2.0 billion USD in 2021 and will reach $4.0 billion USD by 2027 (CAGR of 14.6%).[2] ; an Indoor Air Quality Monitors, which was estimated at $3.7 billion USD in 2020 and projected to reach $6.4 billion USD in 2027, growing at 8.2% CAGR.[3] By executing on these promises, we believe these revenue goals are achievable."

International Endeavors Corporation ("IEC") is a technology holdings company focused on Clean Energy, Crypto, and A.I. Specializing in solar technology, battery storage, as well as clean energy crypto mining options for both on & off grid. We're currently implementing EV2G / Bi-directional charging options, thus allowing you to use your electric vehicle as a means of a backup battery, or to sell power back to the grid. In 2022 IDVV started to offer its clients a Clean Energy Crypto mining solution. Our Plug-n-Play mining rigs can be installed in existing or current systems and allows the option to sell power back to the grid or mine crypto currency with any power surplus. In 2023 We acquired WITech and SF Corp as part of an expansion into the AI Sector. We are incorporating AI technology into our crypto offerings, and developing a platform for AI Content Marketing. The Company currently is reporting its financial information on OTCMarkets. Our filings can be seen at https://www.otcmarkets.com

SmallCapVoice.com Inc. (“SCV”) announces the availability of an interview with Jonathan Bates, chairman and CEO of BitMine Immersion Technologies, Inc. (OTC PINK:BMNR) (“the Company”), a technology company specialized in immersion technology for bitcoin mining. With immersion technology, servers run fully submerged in a dielectric fluid that efficiently cools the machines. Removing heat in this manner allows for superior machine output and energy efficiency compared to conventional mining processes, ultimately improving yield and margins. Speaking with SCV's Stuart Smith, Bates provides an intriguing look at BitMine, which is likely the first specifically branded immersion public company, before diving into the state of the bitcoin industry and where the Company fits in. “This is the future of mining. A lot of bigger companies ... have been touting their newly found expertise in immersion. Our team has been doing this for five years, even though this company is new,” Bates says. As discussed in the interview, his confidence in the Company and his team is further demonstrated by management's decision to work for equity rather than draw a salary. The interview also highlights BitMine's recent milestones, operational goals for 2023, and other points of interest for the investment community. “We represent a thematic play in the most cutting-edge version of bitcoin mining itself. Outside of the futures for bitcoin and ETFs, it's the miners that are the public market representation,” he says. “Our play is a peripheral, smaller, potentially, ideally more upside way to thematically play bitcoin … If you line us up against the other miners, our marketcap is a lot smaller - thinner float and such - but I think we've got a lot of potential upside there.”

Nightfood Teams Up With Sonesta International Hotels Corporation to Offer Sleep-Friendly Snacks Across Multiple Hotel Brands Eighth Largest Hotel Company in the US Launching Nightfood in Sonesta Select, Sonesta ES Suites and Sonesta Simply Suites Managed Properties Nightfood is pioneering the category of sleep-friendly nighttime snacking. Over 80% of Americans snack regularly at night, resulting in an estimated 700 million nighttime snack occasions weekly, and an annual spend on night snacks of over $50 billion. The most popular choices are ice cream, cookies, chips, and candy. Recent research confirms such snacks, in addition to being generally unhealthy, can impair sleep, partly due to excess fat and sugar consumed before bed. Nightfood's sleep-friendly snacks are formulated by sleep and nutrition experts to contain less of those sleep-disruptive ingredients, along with a focus on ingredients and nutrients that research suggests can support nighttime relaxation and better sleep quality. The brand is currently focused on establishing widespread national distribution of Nightfood ice cream, cookies, and other snack formats in the hotel vertical. Hotels are increasingly focused on supporting guest wellness. The Company believes one important way for hotels to do that is by offering sleep-friendly snacks in their grab-and-go lobby shops. With an estimated 56,000 hotels across the United States, expanding distribution into a significant number of those hotels is expected to lead to profitability, consumer adoption of the nighttime snack category, and a strategically defensible position from which category leadership can be maintained. Questions can be directed to investors@Nightfood.com By signing up at ir.nightfood.com, investors can receive updates of filings and news releases in their inbox.

SmallCapVoice.com, Inc. (“SCV”) today announces the availability of a new interview with Marc Hazout, president and CEO of SusGlobal Energy Corp. (OTCQB: SNRG) (“the Company”), to highlight a strategic appointment to its board of directors and recap significant corporate achievements. As Leaders in the Circular Economy ®, SusGlobal is focused on reducing greenhouse gases and diverting organic waste streams from landfills, processing them into regenerative products such as fertilizer. Management's mission is to grow the Company into a significant sustainable waste-to-energy and regenerative products provider and a trusted brand for fertilizer, soil, and aquaculture market. To this accord, SusGlobal recently welcomed to its board of directors Bruce Rintoul, former senior vice president of operations of Veolia North America, where he led the transformation of U.S. and Canadian energy generation, water/wastewater management, hazardous waste, and environmental service businesses through operational and financial successes that resulted in the divestment of several Veolia businesses in North America. Speaking to SCV's Stuart Smith, Hazout explains the significance of his spot on SusGlobal's board. “Bruce is a very seasoned director. He's ICD designated, so that's important for the company; he's an independent director, so that's important too, certainly for our prospective uplifting,” he states. “Veolia is one of the biggest operators in North America – with a $20 billion market cap - in terms of these types of facilities. So, Bruce's addition, of course, will create significant shareholder value. There's no doubt in my mind, certainly with the direction we're going...we believe that this validates everything that we've been saying, and that is the intrinsic value of our environmental compliance approval licenses.” The interview is chock full of additional information pertinent for existing and potential shareholders, such as the Company's endorsement from Hall of Fame golfer Ernie Els and how his role as brand ambassador further supports the Company's expansion initiatives, its progress toward uplisting to the Nasdaq, and more.

PrPrincipal Solar is a strategic investor in and acquirer of organizations and technologies that support next-generation opportunities in traditional, renewable, and clean energy sectors as well as an acquirer and operator of undervalued petroleum-producing properties. For further information, please visit the Company's website at www.pswwenergy.com.

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Christina Moore, director of PawnTrust, a Dinewise Inc. (OTC:DWIS) company. Along with an impending name and ticker symbol change to reflect its focus, PawnTrust is fine-tuning its operations to disrupt the global pawn shop market.    Speaking with SCV's Stuart Smith, Moore explains how PawnTrust evolved from its financing origins to also become a data intelligence platform in the pawn and microlending vertical, a model under which the company achieved revenue growth of 400% in 2022 and could see revenues of more than $10 million in the year ahead. As part of its expansion, Pawn Trust is adding experienced members to its management team and building a base of partner pawn shops and helping them pivot from their antiquated methods to grow their sales and market reach through PawnTrust's digital marketplace. “We look to have 1,000 pawn partners in 2023 and help them generate at least $120,000 in incremental sales per year by being on the Pawn Trust marketplace,” Moore says. “By doing that, which is very conservative, Pawn Trust will create revenue in excess of $10 million. At PawnTrust, we just throw the party. We bring the buyers and sellers together and we make our revenue through a fee that is charged to the pawn shop monthly. PawnTrust is a perfect example of necessity, meeting creativity.”

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new audio interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT), to discuss the positive FDA feedback on BriaCell's pivotal study for lead clinical candidate Bria-IMT™ in combination with a checkpoint inhibitor could greatly accelerate the path to commercialization. Successful completion of the pivotal study could be followed by a Biologics License Application submission and commercialization. Pivotal study's primary endpoint to be linked to survival improvement. “We're treating patients with very advanced breast cancer,” Dr. Williams says. “These are patients who have failed at least two prior therapies, but most of them have failed on the average of six to seven prior attempts of therapy for their metastatic breast cancer. These are very difficult-to-treat patients. Their life expectancy is very short; many of them would otherwise be going on hospice.”

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND) (FWB: CWY), to discuss the biotech company's use of non-hallucinogenic psychedelic compounds to treat physical and mental health, including addiction. Clearmind's intellectual portfolio consists of seven patent families. Its lead candidate, CMND-100, is derived from 5-methoxy-2-aminoindane (MEAI), a psychoactive molecule that exerts a euphoric alcohol-like experience and a reduced desire to consume alcohol. CMND-100 is headed for clinical trials in early 2023 as a potential treatment for alcohol-use disorder (AUD), and Clearmind is also exploring the use of its MEAI-based compound to treat cocaine addiction and depression. Earlier this month, Clearmind was granted a patent from the United States Patent and Trademark Office (USPTO) for the use of its proprietary MEAI as an alcoholic beverage substitute. Speaking with SCV's Stuart Smith, Dr. Zuloff-Shani explains the global need for such treatment. “The number of alcoholics is striking,” she says. “We're talking about millions around the world. Alcohol consumption contributes to 3 million deaths each year globally. It is the third leading, preventable cause of death in the U.S. and the yearly cost is enormous – around $200-$250 billion and that's in 2010.” Despite the statistics, Dr. Zuloff-Shani says that existing treatment options in this largely underserved market are largely ineffective. “You would think that a huge problem probably has a lot of treatments to offer,” she explains. “But it's just the opposite. Since 1950, only three treatments were approved by the FDA. I cannot say that any of them are very effective or have no adverse events associated with it.” In pre-clinical studies, however, MEAI has demonstrated promising efficacy in individuals who struggle with alcohol, helping to break the addiction cycle. Clearmind's interest in the component came from the testimonials of people who purchased it to better manage their alcohol consumption. As Dr. Zuloff-Shani explains in the interview, Clearmind paid attention to those experiences and the company selling the MEAI component online. Convinced of MEIA's potential as a safe treatment option, it then acquired certain worldwide patents of MEAI used that information as an entry point for its own compound. Now, Clearmind is working on an Investigational New Drug (IND) application with the FDA as it advances toward clinical studies of MEAI next year. “Usually when you develop a compound, you start from the other direction. You have an idea. You develop a compound and then you go to petri dishes and to animals, and finally you walk that you will have the same signal as, as you had in animals and in petri dishes in humans,” explains Dr. Zuloff-Shani. “Here, we are just doing the reverse process. We understand [MEAI] has the potential to be effective and safe … we decided that we want to do it in a safe place and take the FDA route.” Smith then shifts the conversation toward Clearmind's most recent developments and the strength of its management team, staff and scientific advisory board. Dr. Zuloff-Shani describes the structure of Clearmind's operations and how it benefits corporate objectives and overhead. “We have a very impressive staff in the company,” says Dr. Zuloff-Shani, who is well-versed in navigating regulatory pathways through her more than 20 years of experience in the biotech and pharmaceutical industries. “We don't have a lot of people, and this is by choice. We prefer to work in outsourcing because that enables us to manage our expenses better. On the other hand, it allows us to really collaborate in every field that we are dealing with.” The interview concludes with what Clearmind expects to achieve in the New Year and how it plans to overcome the challenges associated with advancing toward clinical trials.

CEO, Cliff Emmons, and COO, Karen McNemar discuss the recently announced financial results for its third quarter ended September 30, 2022. Cliff Emmons, CEO of IIOT-OXYS, Inc. (Oxys) stated, "We're pleased to announce that we kept our revenue promise for the quarter ended September 30th, 2022. As predicted, third quarter revenue exceeded that in second quarter. This makes two consecutive quarters of revenue, which the Company hasn't done since before the pandemic. We are pleased that the momentum of the second quarter's revenue continued into the third quarter and we expect it will continue through the fourth quarter. We also expect revenue for the second half of 2022 will exceed that generated in the first half of 2022. In total, we expect that total revenue for 2022 will be approaching 2019 levels. We continue to gain traction with strategic partners, customers, and potential customers in our key two markets: Smart Manufacturing / Industry 4.0 and Structural Health Monitoring (SHM). These are both high growth markets. Market research shows the worldwide Industry 4.0 market in 2021 was $64.9 billion USD and is projected to be $165.5 billion USD by 2026 (20.6% CAGR)1. Also, the worldwide Structural Health Monitoring industry was $2.0 billion USD in 2021 and will reach $4.0 billion USD by 2027 (CAGR of 14.6%)2. Through our collaborations with Aretas Sensor Networks, we have access to a third market, Indoor Air Quality Monitors, which was estimated at $3.7 billion USD in 2020 and projected to reach $6.4 billion USD in 2027, growing at 8.2% CAGR3."

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT), to discuss three key achievements that support the Company's continued growth. The Company recently announced positive initial efficacy data in its 2021-2022 cohort of 12 advanced breast cancer patients. Disease control, tumor shrinkage, and potential survival benefit were observed amongst 12 patients in the Phase I/IIa clinical study of Bria-IMT™ in combination with Incyte's retifanlimab. Bria-IMT™ regimen in combination with Incyte's retifanlimab produced evidence of disease control, tumor shrinkage, and potential survival benefit amongst BriaCell's recent 12 patient cohort in advanced breast cancer. The study, recently awarded U.S. Food and Drug Administration ("FDA") fast track designation, continues with additional clinical data forthcoming. The regimen remains well tolerated as recently reported in Phase I evaluation. 70% of patients showed either disease control or progression-free survival (PFS) benefits compared with their last therapy. Prior to enrollment, the 12 patients in the cohort had already been unsuccessfully heavily pre-treated with at least 2 prior therapy regimens, further underscoring BriaCell's positive patient outcomes.

Progressive Care Shareholder Conference Call and Business Update November 14, 2022. Co-vice chairman and CEO, Alan Jay Weisberg, stated, “It has been an exciting quarter for the company and we are really looking forward to sharing developments with our shareholders.” Progressive Care Inc. (OTCQB: RXMD), through its subsidiaries, is a Florida health services organization and provider of prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long-term care facilities, and health practice risk management.

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with David Massey, CEO of Solar Integrated Roofing Corp. (OTC:SIRC), to discuss the Company's recent news, financial position and other points of shareholder interest. SIRC is an alternative energy company that specializes in commercial and residential projects throughout the United States. Utilizing a successful growth-by-acquisition strategy, the Company's breadth of offerings has expanded to include sales and installation of solar energy systems, battery backup and electric vehicles (EV) charging stations to roofing, HVAC and related electrical contracting work. Speaking with SCV's Stuart Smith, Massey outlines SIRC's five revenue streams and their contribution to the Company's record second-quarter performance, where it grew its revenues by 746 percent to $66.3 million with net income of $18.9 million. Paced to hit over $225 million in full-year 2022 revenues, the Company is also taking steps to become fully reporting and to uplist to a major exchange. “We filed the Form 10K and we'll have a steppingstone to the OTCQB or the OTCQX for a while as we solidify the management team, grow the revenues and check out the market conditions,” Massey explains. “I think 2023 NASDAQ is definitely in the picture, but again, the market conditions are very important for that step.” As SIRC moves toward its operational and financial goals, the Company is aligning its management team with its potential. Earlier this month, SIRC named Stefan Abbruzzese as its new president. An experienced operations and commercial leader with decades of experience, Abbruzzese will provide extensive knowledge to SIRC's expansion. “He's a topnotch executive,” Massey says. “Our second focus this year is getting the correct funding in place so we can continue to grow and move our pipeline, and Abbruzzese is an expert in lending. He brings a lot of expertise and experience in that field and and is just a great leader.” SIRC intends to move into the coming year with the funding, cashflow and revenue growth it needs to surpass its already historic corporate performance. “We're looking to wrap up our funding process … and get cashflow positive. We're very close to that now, and we're looking to really blow the doors off the revenue this year,” Massey says, noting his expectations for continued revenue growth. “Looking forward, 2023 could be twice as good as 2022.”

SmallCapVoice.com, Inc. (“SCV”) today announces the availability of a new interview with Marc Hazout, CEO of SusGlobal Energy Corp. (OTCQB: SNRG) (“the Company”), to discuss the Company's milestone achievement in generating revenues from its carbon credits monetization initiative. As Leaders in the Circular Economy ®, SusGlobal is focused on reducing greenhouse gases and diverting organic waste streams from landfills, processing them into regenerative products such as fertilizer. As reported in September, the Company's SusGlobal Belleville subsidiary has generated roughly 105,000 Verified Emission Reductions and Removals (VERRs) and recently sold its first carbon credits, adding to SusGlobal a third revenue stream. The sales will be reflected in SusGlobal's upcoming third-quarter earnings Hazout tells SCV's Stuart Smith, and the Company anticipates repeating this financial milestone annually. He also notes additional near-term corporate objectives, including uplisting to the NASDAQ and advancing its Hamilton processing facility to achieve a similar revenue pattern. “It is very exciting times at the Company, and I think the market reflects that,” Hazout says. “I think we're seeing the valuation continue to increase incrementally … We have the capacity to increase the amount of tonnage that we're processing and therefore it will reflect in an increase of carbon credits, we're able to generate more VERRs. When Hamilton is online in 2023, we'll register that facility to do the same thing and repeat it. We now have the expertise to do that.”

AUSTIN, Texas (Sept. 21, 2022) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Ryan Schadel, CEO of Metavesco Inc. (OTC PINK: MVCO) (“the Company”), a web3 enterprise invested in decentralized finance (DeFi), to discuss the Company's operations, digital assets and corporate outlook. The full interview can be heard at: https://www.smallcapvoice.com/2022-interview-mvco-metavesco-mvco/. Speaking with SCV's Stuart Smith, Schadel explains how Metavesco generates revenues through liquidity pools alongside its focus on crypto staking, NFT and the Metaverse. “There's so much being built in this space and we're trying to cast a wide net and capture what we can as this space matures and becomes more mainstream,” he says, offering insight into the broader crypto market and what the Company expects to achieve from its investments and position as an early mover. “When I look at 2023, it's really about a year of mass adoption. I think we will see the protocols that we've invested in achieve wider adoption rates. I believe that next year we will see some pretty significant returns in the money that we've put to work and that will ultimately benefit shareholders,” he says. “There is no other publicly traded cryptocurrency liquidity provider in the United States; we are the first and I'm certain we won't be the last. That means we have some proving to do, and so my hope for next year is that when shareholders and potential shareholders look at how we did, they think ‘Wow, this model is great. Metavesco is really a first-mover and is generating returns for shareholders.' Ultimately, that's my job.”

AUSTIN, Texas (Sept. 20, 2022) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Yftah Ben Yaackov, CEO of BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (CNSX:BYND.CN) (“BYND” or the “Company”), to discuss the Company's operations, innovations and outlook for the coming year. The full interview can be heard at: https://www.smallcapvoice.com/2022-interview-bynd-cannasoft-bcan/. BYND is an Israel-based integrated software/cannabis company focused on the development of its customer relationship management (CRM) platform for the medical cannabis market. Speaking with SCV's Stuart Smith, Ben Yaackov discusses the Company's 20 years in the big data market and the decision to extend its expertise to growers, suppliers and researchers of medicinal cannabis. “BYND made a strategic decision about two years ago to try to arrange a software that will solve many problems that growers of medical cannabis have. Currently in the final stage of development, the software manages databases while integrating algorithm for maximizing and streamlining growing farms in general, and particularly medical cannabis farms,” he says. A professional lawyer since 2004, Ben Yaackov also has experience in project management and trading in medicinal cannabis. This combination has resulted in several corporate achievements and provides support for BYND's objectives moving forward. “2020, 2021 and the first half of 2022 were challenging and exciting at the same time,” he explains, highlighting BYND's listing on the Canadian CSE and NASDAQ capital markets earlier this year. The Company also recently acquired an Israel-based company with a patent-pending CBD treatment product, the EZ-G device, representing a $28 million transaction that Ben Yaackov says will add value to BYND as it seeks regulatory approval and patent registration. The EZ-G device uses proprietary software (provisional application) to regulate the flow of low-concentration CBD oils into the soft tissues of the female reproductive system to treat candida, dryness, scars and other health issues. “This, together with our great development in the software field and the preparations of obtaining the license to practice medical cannabis, makes the last two years a period of great prosperity and success,” he adds. “We are confident that it will bring significant value for the Company in the upcoming year.” Wrapping up 2022 and moving into 2023, Ben Yaackov says he expects to see continued progress in the Company's software development and sales expansion. Additionally, BYND is in the final stage of obtaining a license to engage in the sale of medical cannabis without connecting with the substance. “This is a special license that few have in Israel. It allows you to establish products in the medical cannabis field, a label of your own, through an existing grower that has the license to grow medical cannabis in Israel,” he explains. “That will bring us another revenue from the side of selling medical cannabis products, and above all that, I believe that we will significantly advance the new project and finish the patent registration and put other necessary regulations and build a prototype until the end of the fourth quarter of 2023.”

CEO, Cliff Emmons, and COO, Karen McNemar discuss the recently announced financial results for its second quarter ended June 30, 2022. Cliff Emmons, CEO of IIOT-OXYS, Inc. (Oxys) stated, "Our revenue for the quarter ended June 30, 2022 exceeded the total revenue for 2021, as was anticipated in our Quarterly Report on Form 10-Q for the first quarter of 2022. We continue to gain traction with strategic partners, customers, and potential customers in our key two markets: Smart Manufacturing / Industry 4.0 and Structural Health Monitoring (SHM). These are both high growth markets. Market research shows the worldwide Industry 4.0 market in 2021 was $64.9 billion USD and is projected to be $165.5 billion USD by 2026 (20.6% CAGR).1 Also, the worldwide Structural Health Monitoring industry was $2.0 billion USD in 2021 and will reach $4.0 billion USD by 2027 (CAGR of 14.6%).2 Through our collaborations with Aretas Sensor Networks, we have access to a third market, Indoor Air Quality Monitors, which was estimated at $3.7 billion USD in 2020 and projected to reach $6.4 billion USD in 2027, growing at 8.2% CAGR.3" Some Key Accomplishments in 2022 YTD include: Our Structural Health Monitoring business continues to gather momentum, receiving a contract extension with a New England State's DOT for Bridge Monitoring announced in the first quarter for monitoring throughout the second quarter, which generated this quarter's revenue. A proposal for monitoring and equipment upgrades for the 2022 to 2023 fiscal year was submitted in the second quarter, and we anticipate its formal approval in the second half of 2022. We received verbal approval to continue invoicing monitoring fees into third quarter, while awaiting formal written approval. The Canadian Indoor Air Quality Sensor and IIoT Platform company, Aretas Sensor Networks, with whom we entered an NDA in the first quarter, continues to progress well. In addition to the initial collaborative agreement signed in the first quarter, we signed an algortihm development contract in the second quarter which will generate revenue in our third quarter. We continue to explore additional collaborations that we expect to move forward with this year. Our CEO, Cliff Emmons, and COO, Karen McNemar, both renewed their employment contracts in June, ensuring stable experienced leadership focused on long-term growth. "We believe the underlying strengths of the Company are gathering momentum for expected growth. We will keep a steady focus on prospecting, submitting proposals, and securing Proof of Concepts (POCs). It is anticipated that the momentum of the second quarter's revenue will continue into the third quarter and the second half of the year. We expect that our third quarter revenue will match or exceed this quarter's revenues, and revenue for the second half of 2022 will exceed that generated in the first half of 2022. In total, we expect that total revenue for 2022 will exceed that of 2019" concluded Mr. Emmons.

MIAMI, FL, Aug. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company (the “Company” or “Progressive Care”), is pleased to announce that the Company has scheduled an investor conference call at 4:30 PM ET on Thursday, August 11, 2022. Chairman and CEO, Alan Jay Weisberg, stated, “We are looking forward to updating you on the results of the second quarter, our prescription growth, and recent developments that we believe will continue to accelerate our growth as a diversified technology-centric healthcare organization”.

AUSTIN, Texas (August 2nd, 2022) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Nika Jaksic, COO of BioLife Sciences Inc. (OTCPK: BLFE) (the “Company”), to provide an overview of the Company's operations and corporate momentum. The interview includes discussion on BioLife's plans for uplitsing and its upcoming launch of an innovative product to improve cannabis cultivation. BioLife is a commercialization accelerator focused on moving innovative products from the lab to small scale production while also conceptualizing and innovating its own line of products. Speaking with SCV's Stuart Smith, Jaksic explains how the Company's wide approach to this model creates unrestrictive market opportunity. “We like to take disruptive ideas and grow and expand those ideas into marketable products that aim to enrich the lives of our customers and our communities, whether that's a new concept being developed from scratch, or simply us reinventing the wheel,” he says. “We're not going to limit ourselves to any one product or any one industry. If we have a marketable idea that will help our customers and benefit our shareholders, then we will pursue.” Jaksic next describes how a corporate transformation, brought-on by a leadership change in 2020, has enhanced business development. This growth includes an acquisition strategy that enables the introduction of new and innovative products to the market. As the Company advances on these opportunities, it is now prepared to broaden its exposure to the investment community. “Uplisting to the OTCQB has traditionally resulted in greater liquidity, increased transparency, upgraded reporting standards, better overall awareness of the company to our larger group of investors, including venture capitalists,” he says. “Aside from that, we are going to continue developing our new natural health products division so we can keep expanding our company and its offerings in the coming years. And of course, we're going to introduce new and exciting products to the marketplace so we can increase the Company's revenue. We're excited about what the future holds for our Company and its shareholders.” A high-potential aspect of BioLife's future pivots from its acquisition of Health Box LLC, a health products company founded by Jaksic in 2020, along with a new focus on copper-infused textiles. “When I say we ‘reinvent the wheel,' that is exactly what we accomplished with our copper infusion process and the resulting line of product,” Jaksic says, explaining how the COVID-19 pandemic generated greater demand for products utilizing copper's antimicrobial properties. While there are many copper-infused textiles in the market, BioLife distanced itself from competitors by offering superior and innovative copper-infused textiles. The root innovation is the Company's unique copper infusion process, which significantly improves copper distribution throughout the fibers of the fabric while reducing costs and time. “We can use infusion in the traditional way to design our copper-infused garments from scratch … or we can do it by obtaining preexisting garments and infusing them with copper after they have been designed,” Jaksic says. This capability enables BioLife to pursue partnerships with other companies that want to improve the quality and efficacy of their products beyond industry standards. Based on this technology, the Company intends to initiate three novel product launches within the next year, starting with an antimicrobial copper-infused fabric gardening pot. This product launch will position the Company before a new market of customers in the $300+ billion global cannabis cultivation market. “The copper works as a fungicide that eliminates harmful microbes while simultaneously boosting the beneficial organisms that thrive in the soil. The results are healthier and stronger plants with larger yields as well as healthier soil,” Jaksic explains.

SmallCapVoice.com Inc. ("SCV") announces the availability of a new interview with Rhett Doolittle to discuss the recent Q3 results for Business Warrior Corp.'s (OTC PINK:BZWR) ("the Company") and the driver's for success moving forward. He is joined by Business Warrior's Global Head of Technology Timothy Li who provides he unique insights as the newest member of the BZWR team. Business Warrior is a SaaS company providing small businesses in the United States with a suite of data-driven marketing and next-generation, funding solutions to boost local market dominance. Founded in 2014, Business Warrior is singularly focused on offering locally targeted lead generation marketing and funding solutions that fuel small business growth. By using next generation machine-learning and native software, Business Warrior has made growth funding and conversion marketing accessible for thousands of under-resourced and under-funded small business owners. For more information, visit BusinessWarrior.com.

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT), to discuss key achievements that support the Company's continued growth and his recent purchase of the Company's warrants. BriaCell is a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer. Speaking with SCV's Stuart Smith, Dr. Williams first detailed his reasoning behind the purchase of his Company's stock. Williams stated, "With my training in immunology and extensive background in the field, I have already seen technologies worth paying attention to, and I know what we have here at BriaCell is something very special." Dr. Williams also discussed the recent news regarding the manufacturing service agreement with Waisman Biomanufacturing at the University of Wisconsin–Madison (Waisman), to manufacture Bria-Pros™, BriaCell's off-the-shelf personalized immunotherapy for prostate cancer, and the collaboration agreement with Harvard Medical School in support of a project led by Dr. Joan S. Brugge attempting to discover new targets that may lead to the development of novel anti-cancer treatments.

SmallCapVoice.com Inc. (“SCV”) announces the availability of an interview with Greg Reimer, newly appointed Chairman of the Board to Canadian cobalt exploration company Fuse Cobalt Inc. (“the Company” or “Fuse”) (TSXV:FUSE, OTCQB:FUSEF FRA:43W3) and current CEO of Surge Battery Metals Inc. Speaking with SCV's Stuart Smith, Reimer gives a quick review of Fuse and how his professional background is complementary to the Company's business model and growth track. “I've had a lot to do with mining policy and operations, as well as energy. I'm well-suited for this field and look forward to serving on the board,” he says, then moving to discussion of Fuse's Glencore and Teledyne properties. “A significant increase in cobalt prices has given the Company the ability to refocus and plan for our 2022 exploration program … These two projects have high cobalt intersections that were identified in previous drilling programs and we're currently securing drilling resources for a fall drilling program.” Reimer also gives insight into the broader battery metals market and discusses increasing demand for electric vehicles and battery-powered consumer products.

Business Warrior Leadership Discusses Acquisition of FinTech SaaS Company, Alchemy Technologies Business Warrior Corp. (OTC: BZWR), the source for small businesses in America to get more customers, today announces the acquisition of Alchemy Technologies, a global FinTech software as a service (SaaS) company. The acquisition strengthens Business Warrior's core marketing and lending software while expanding the Company's brand and services to meet global demand. Alchemy specializes in creating end-to-end, cloud native lending experiences for other FinTech companies, merchants and banks. The company installs its core solution to a number of different verticals, including: Personal loans Point of Sale Financing Health and Beauty Financing Construction Loans Solar and Home Improvement Financing Small Business Lending Skillset Financing Crowdfunding Platforms In working with Alchemy to develop its Business Warrior Funding lending platform earlier this year, Business Warrior identified Alchemy as an attractive acquisition opportunity, noting its operational and financial performance.

IIOT-OXYS, Inc. Leadership Conduct New Audio Interview Answering Shareholder Questions and Provide Overview of Recent Financial and Operational Results IIOT-OXYS, Inc. (OTC PINK:ITOX) (“the Company”) announced it has conducted an audio interview to discuss its recent financial results, answer shareholder questions and provide an operational outlook moving forward. IIOT-OXYS, Inc. leadership CEO, Cliff Emmons, and COO, Karen McNemar, who also fill the roles of interim CTO and interim CFO respectively, each provided their personal insights into recent news and business operations. Furthermore, each of them fielded several questions submitted to Company by its shareholders.

CEO Mike of O'Shea of Xcelerate, Inc., a development stage startup focused on the development of cutting-edge medtech applications, met with SmallCapVoice.com to discuss the recent appointment of a new board member and the acquisition of a rather sizeable patent portfolio. This acquisition expands upon Xcelerate's mission of acquiring innovation in the engineering and patent stages of production for further development and commercialization within the medical industry. O'Shea was joined by Jon Wilken, president and CEO of HS Pharmaceuticals, LLC. They opened up about his new role as an advisory board member for Xcelerate and what has led up to the acquisition to this point. Wilken spent more than 30 years in the supermarket retail industry before leaving the business in 2002. He also spent more than 10 years teaching entrepreneurial leadership at Clemson University. Venturing into the biopharmaceuticals industry, he then left academia and accepted the role as CEO and president of HS Pharmaceuticals, where he led the charge in the discovery of many early-stage drugs and immunotherapies. As CEO of HS Pharmaceuticals, Wilken would focus on innovative and breakthrough treatments for chronic wounds and conditions that affect the human body on a molecular level, creating dermatological products for chronic wounds, burns, and drug-resistant infections, as well as patented formulas for some of the most game-changing cosmetics and beauty products on the market. Throughout the years, the company would also focus on oncology, autoimmune therapies, cancer treatment and bone regeneration for both man and animal – many of which would be developed in collaboration with scientists at the Lakehead and Cambridge Universities. In a previous press release, O'Shea stated that "HS Pharmaceuticals has been shepherding these patents for the last 10+ years in conjunction with world-renowned scientists and universities, and we are excited to take this amazing intellectual property to the next level." "The Board and I welcome Jon,” he continued, “and look forward to collaborating with him on the various projects and, more especially, assisting in assimilating the recently acquired patent portfolio into our business plan. Jon has spent years coordinating the development of these patents and coordinating the efforts of various research scientists and universities." For the last 2 years, both companies have been in negotiation, making sure the climate was suitable when merging HS Pharmaceuticals into the fold of Xcelerate and its growing list of revolutionary technologies. Since announcing that it had signed a purchase agreement to acquire a global portfolio of patents, patents pending, and technology licenses from HS Pharmaceuticals LLC, Xcelerate would go on to add a number of patents and patents pending across the U.S., Canada and Eurasia, which can be found here. “We're excited that we're excited about this relationship with Mike and his team,” states Wilken. “We're looking forward to our scientists, our research people, our PhDs working with the people that Mike has on board. It's going to be a great collaboration.” Xcelerate plans on taking the research conducted by HS Pharmaceuticals and its entire portfolio of patents to the next level. Together, the companies have devised a plan that is expected to become of great interest to major pharmaceutical houses across the industry.

MIAMI, FL, May 17, 2022 (GLOBE NEWSWIRE) -- via – Progressive Care Inc. (OTCQB: RXMD) (the “Company”), a personalized healthcare services and technology provider, today announced financial and operational results for the three months ended March 31, 2022. Key Financial Highlights for the Three Months Ended March 31, 2022 compared to the same period in 2021 Revenue increased by 5%, from $9.6 million in 2021 to $10.1 million in 2022 Gross margin decreased slightly to 24% in 2022 from 25% in 2021 Operating loss decreased by 79%, from $0.6 million in 2021 to $0.1 million in 2022 Adjusted EBITDA increased by 53% from $66,349 in 2021 to $101,646 in 2022 Business Highlights Strengthened management team with industry experts Expanded corporate services with enhanced COVID-19 platform capabilities Approved as COVID-19 test vendor in the U.S. for travel to Beijing Winter Olympic Games Engaged with Alteryx software implementation partner Aimpoint Digital to streamline healthcare data management workflows. Partnered with Podium to boost customer satisfaction, efficiency and brand awareness Gained long-term pharmacy contracts with major payors Announced expansion plans into the rapidly growing multi-billion dollar Remote Patient Monitoring space Gained SEC reporting status on April 11, 2022 through the filing of Form 10-12G Summary Financials for the Three Months Ended March 31, 2022, as Compared with the Three Months Ended March 31, 2021

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Arman Tabatabaei, CEO Cannabis Global Inc. (OTC Pink: CBGL), to address questions from the Company's shareholders and the investment community. Speaking with SCV's Stuart Smith, Tabatabaei discusses the challenges associated with corporate growth, keeping up with regulatory changes, and fund raising. In conjunction with all of CBGL's progress, Tabatabaei believes transparency with shareholders is crucial. “Right now, our main challenge is managing growth and I think that's a good of a problem to have,” he says. “We're growing very quickly, and we're caught between financing the business, hiring adequate personnel, managing the distribution channel. And you know, of course the regulatory environment that is inherit to the cannabis industry … We've been fortunate to receive adequate financing thus far, but in a nutshell, I will tell you that our biggest challenge is to manage the growth relative to raising capital so we can ensure that we can meet our goals.” The interview touches on a sweeping range of topics to keep shareholders abreast of CBGL's corporate developments. As the Company continues its growth trajectory, Tabatabaei says he plans to hold more Q&A sessions and concludes the interview by welcoming investors and shareholders to send additional questions to SSmith@SmallCapVoice.

Marc Hazout, Founder, Chairman and Chief Executive Officer of SusGlobal Energy Corp. ("SUSGLOBAL" or the "Company") (OTCQB: SNRG), the developer of SusGro™, an award-winning, revolutionary pathogen-free organic liquid fertilizer, called into SmallCapVoice.com, to discuss the recent news and milestones for the Company. Recently, SusGlobal announced that its wholly-owned subsidiary, SusGlobal Energy Hamilton Ltd. ("SusGlobal Hamilton"), continues the development of its 51,535 square foot facility on 3.26 acres (the "Property") located at 520 Nash Road North, in Hamilton, Ontario, which includes an Environmental Compliance Approval ("ECA") to process up to 65,884 metric tonnes per annum of organic waste into regenerative products as part of the Company's circular economy model and continued climate change initiatives Earlier this year, the Company announced that its wholly-owned subsidiary, SusGlobal Energy Canada Corp. ("SusGlobal Canada"), has entered into a non-binding letter of intent to acquire a soil media, plant nutrients, and amendments producer approved for organic use and specifically formulated for producing high-quality fruit and flowering crops (the "Target") for an aggregate purchase price of US$15,701,885 (CA$20,000,000) (the "Acquisition").

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Michael O'Shea, CEO of Xcelerate, Inc. (OTC Pink: XCRT) and Dr. Dilan Ellegala Xcelerate Advisory Board Member and co-founder of AfiyaSasa Africa, LLC ("ASA). The interview covers the Xcelerate announced has acquired majority control in AfiyaSasa Africa, LLC. ("ASA"), a medical technology and virtual health company that they believe is positioned to help patients in developing countries in Africa meet their medical needs by extending the reach of physicians and hospitals through the Company's technology. Dr. Dilan Elegalla, one of the Managers of this LLC, has relocated to Tanzania to establish a pilot program for the ASA System in that country. XCRT is now excited to announce that, thanks to the efforts of Dr. Elegalla and his team, ASA now has verbal commitments to launch AfiyaSasa Tanzania as a pilot in 4 hospitals and likely in a fifth: KCMC (Kilimanjaro Christian Medical Centre). NSK Hospitals, ALMC (Arusha Lutheran Medical Center), and Haydon Lutheran Hospital. These four institutions represent a catchment area of approximately 20 million people. Once the pilot program is established and tested, they would continue with a rollout into the institution as well as their outreach clinics. A fifth hospital, Jakaya Kikwete Cardiac Institute, has expressed a strong interest in joining the pilot program. JKCI is a specialty hospital with countrywide reach (60 million Tanzanians plus regional patients).

Progressive Care is pleased to announce that the Company has scheduled an investor conference call at 4:30 PM ET on Monday, March 28, 2022. MIAMI, FL, March 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company (the “Company” or “Progressive Care”), is pleased to announce that the Company has scheduled an investor conference call at 4:30 PM ET on Monday, March 28, 2022. Chairman and CEO, Alan Jay Weisberg, stated, “I believe 2021 was a challenging year for Progressive Care. Our team was able to complete complex implementation of the pharmacy system so that the company can get back to growing the pharmacy business, successfully achieve record COVID-19 revenues and position itself to become an SEC reporting company. We are looking forward to providing our shareholders with a more detailed update and share the Company's vision for 2022 during the conference call.”

Intercept Music Shows Scalable, Sustainable Growth and Investment The Company's financial statements for the year ended Dec 31, 2021 show strong operational performance and financial position for the core Intercept Music business, which provides record label services to the independent music market. In the context of the continued strong performance of the music industry overall (see below), Intercept Music is ideally positioned for continued and sustainable growth with service offerings that are unparalleled among independent music service companies. As the proof phase of Intercept Music concludes this month, the Company has seen significant increases across many key performance indicators, and has created an infrastructure to accommodate future growth. Highlights of the 2021 financial report include: Increased gross sales more than 70% over previous year; Grew per-artist revenue by 22% over 2020; Converted more than 75% of short-term convertible debt into long debt and equity; Raised more than $1.1 million in new equity financing. Additionally, the Company has expanded and refined its service offerings, with positive results including: Increased customer base, to a current total of 40 independent labels and 300 independent artists; Added branded, turnkey online merchandising stores to enhance artist revenue; Expanded artist marketing services to include playlisting, public relations, advertising, reviews, physical recordings, and more. Operationally, the Company has created a roadmap for future growth and enhanced profitability, as well. Highlights of this side of the business include: Streamlined customer service support, resulting in a 50% decrease in customer service requests; Focused business on labels. As a result of testing initiatives, the Company discovered that compared to individual artists, label customers offer multiple artists, enhanced operational efficiency, and greater resources, among other benefits; Hired a full-time marketing director, as well as additional customer service and marketing personnel, overall tripling staff count; Signed with top-end, outsourced service providers to deliver world-class results in software development, public relations, and investor relations, without additional personnel overhead costs.

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Michael O'Shea, CEO of Xcelerate, Inc. (OTC Pink: XCRT), to discuss how the Company is utilizing artificial intelligence (AI) and other technologies to deliver healthcare to remote areas of Africa. Xcelerate is an innovation and development company that marries non-medical engineering, advancements and systems with MedTech and clinical care within the healthcare industry. Speaking with SCV's Stuart Smith, O'Shea explains Xcelerate's plan to use AI to give the people of Tanzania, Africa, greater access to physicians and medical care. “The software-based system was originally developed by the folks that develop the AI for self-driving cars and we've applied that to a medical use in an essence. This program allows people in remote areas to reach healthcare professionals by the use of any mobile device. It then builds a database on these people. Facial recognition, if they're a returning patient, allows them to input basic triage information and give the physician a head start on being able to treat the patient prescribed medications,” he says. “We expect that we'll have a beta site for the project launched by end of second quarter and expect to be generating revenues before the end of this year. Additionally, we're filing one patent, hopefully in the next week and three others to follow all based on our initial license, but to be used in surgical instruments and retrofitting them to existing surgical, surgical wounds.” The interview also highlights the unique expertise of the Xcelerate team, along with several corporate milestones that are moving the Company toward uplisting to the OTCQB and reaching other corporate objectives.

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Business Warrior Corp. (OTC: BZWR) (“the Company”) to discuss the Company's new $25M funding partnership with Fuel Me, the status of the acquisition of the award-winning marketing agency and an updated timeline for the completion of the Company audit for up-listing to the OTC.QB. Business Warrior is a SaaS company providing small businesses in the United States with a suite of data driven marketing and next-generation, funding solutions to boost local market domination. Founded in 2014, Business Warrior is singularly focused on offering locally targeted lead generation marketing and funding solutions that fuel small business growth. By using next generation machine-learning and native software, Business Warrior has made growth funding and conversion marketing accessible for thousands of under-resourced and under-funded small business owners. For more information, visit BusinessWarrior.com.

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Bill Williams, CEO and Giuseppe Del Priore, MD, MPH, the Company's Chief Medical Officer (CMO)of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT), to discuss the Company goals moving forward relating to its current and upcoming clinical trials including the ongoing Phase I/IIa combination study of BriaCell's lead candidate, Bria-IMT™, with Incyte's checkpoint inhibitors, retifanlimab and epacadostat in advanced breast cancer. In February 2022, the Company announced the appointment of Giuseppe Del Priore, MD, MPH, as the Company's Chief Medical Officer (CMO). Dr. Del Priore is a seasoned healthcare executive with over 25 years of experience in research, drug development, and clinical trials management. Dr. Del Priore's prior work experience includes serving as a biotech Chief Medical Officer, a National Director at the Cancer Treatment Centers of America (CTCA), plus faculty at Indiana University School of Medicine, Weill Cornell Medicine, and New York University School of Medicine. BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.

Over 80% of Americans snack regularly at night, resulting in an estimated 700 million nighttime snack occasions weekly, and an annual spend on night snacks of over $50 billion. The most popular choices are ice cream, cookies, chips, and candy. Recent research confirms such snacks, in addition to being generally unhealthy, can impair sleep, partly due to excess fat and sugar consumed before bed. Nightfood's sleep-friendly snacks are formulated by sleep and nutrition experts to contain less of those sleep-disruptive ingredients, along with a focus on ingredients and nutrients that research suggests can support nighttime relaxation and better sleep quality.

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Joe Abdo, CEO of Stella Diagnostics Inc. (OTC Pink: SLDX) (“the Company”), to discuss how the Company' is raising the standards for precancerous screening of esophageal cancer. Stella Diagnostics is developing diagnostic tools that help physicians determine a patient's risk of disease progression in precancerous indications such as Barrett's esophagus. Barrett's is most often diagnosed in people with gastroesophageal reflux disease (GERD or chronic heartburn), which affects over 60 million Americans (one in four adults) and is the only known precursor of esophageal adenocarcinoma (cancer). The full interview can be heard at: https://www.smallcapvoice.com/interview-stella-diagnostics-sldx/. Speaking with SCV's Stuart Smith, Dr. Abdo explains how Stella Diagnostics' assays quantify the presence of good or harmful protein within biopsy tissue and enhance the current standard of care for Barrett's screening by providing robust molecular information on the hallmarks of cancer development. “When we analyze precancerous tissue, we can inform physicians if that tissue is actually possessive of a carcinogenic molecular properties,” he says. “The screening protocol assesses the cell structure, cell organization, cell differentiation of biopsies retrieved during endoscopies. There's very little if any molecular information that's being retrieved with the current standard screening for people that have precancerous diseases like Barrett's esophagus.” Esophageal cancer is the fastest-rising, deadliest cancer in the United States. Early detection of the disease can significantly increase a patient's survival rate and quality of life, though current routine screening generally catches esophageal cancers in the advanced stages. “Our goal at Stella Diagnostics is to have 100% of patients that progress from this precancerous present to their oncologist in stage one or stage zero, where they can actually be cured and not succumb to this very deadly disease,” Dr. Abdo says. A two-time cancer survivor himself, Dr. Abdo then shares an anecdotal conversation that highlighted the gap between routine screenings and late-stage cancer diagnoses and led to the founding of Stella Diagnostics in 2020. The goal of the Company's diagnostic approach is not to replace standard screening protocols, but to rapidly, cost effectively and non-invasively provide superior molecular information that optimizes patient management strategies and leads to earlier detection. “We want to be used in concert and be a complimentary tool kit for these clinicians to basically make a better-informed clinical decision,” he tells SCV. “When we designed our test, we decided to use a mass spectroscopy because it's very sensitive or requires very little tissue material. … if we can get the right people in the higher risk bucket, then we think that we can ultimately extend and save lives because they would presumably be presenting to their oncologists in the earlier stages.” Next, the interview highlights various investment considerations, including the expertise of Stella Diagnostics' board of directors and executive and research and development teams. “Stella Diagnostics has a deep bench of experience - biotechnology, asset managers, executive leaders - with decades of experience managing and investing in life science organizations,” says Dr. Abdo, who has more than a decade of experience researching molecular oncology mechanisms in gastrointestinal diseases. “They're doing a great job working to position Stella as a standard screening tool for precancerous diseases. … From the regulatory and biotech leadership aspects, and the asset management aspects, all the way through our clinical science and how we're validating and optimizing our tests with the leading medical institutions in the country, I couldn't be happier with the team that we currently have.”

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Cannabis Global Inc. (OTC Pink: CBGL) to discuss the Company's rapid growth and competitive advantages in the cannabis market. Speaking with SCV's Stuart Smith, Cannabis Global CEO Arman Tabatabaei dives into the Company's financial performance and expectations for the current quarter. “We're pretty proud of the way we've been able to conduct business over the past couple of quarters, as it's very clear that we're growing at a very good pace,” he says, referencing strong growth in revenues and total assets. The interview also highlights the new products and strategies that lend weight to Cannabis Global's position as a competitive cannabis innovator. Cannabis Global, Inc. is a Los Angeles-based, fully audited and reporting Company with the U.S. Securities & Exchange Commission, trading under the stock symbol CBGL. We are an emerging force in the cannabis marketplace with a growing product and proprietary intellectual property portfolio. We are marketing and producing Comply Bag, an innovative solution for cannabis storage, transport and tracking. Our subsidiary, Natural Plant Extract (NPE), is a Southern California licensed cannabis manufacturer and distributor which licenses our technologies to produce edibles for the cannabis marketplace. Cannabis Global has filed three non-provisional and multiple provisional patents for cannabis infusion and nanoparticle technologies and continues an active research & development program.

USTIN, Texas (January 25, 2022) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with technology company IIOT-OXYS, Inc. (OTC : ITOX) (“the Company”) to discuss its operations, recent milestones and outlook for 2022. Speaking with SCV's Stuart Smith, IIOT-OXYS, Inc. CEO Cliff Emmons describes the Company's operations and use of machine learning and proprietary algorithms to provide actionable mission critical insights for clients in a wide range of industries. Despite headwinds of the COVID pandemic, IIOT-OXYS, Inc. was able to adjust its footing and hit key growth catalysts that support its core mission. “When we take a look at what we've been able to accomplish in 2021, it's very foundational,” Emmons says. “This was the year we found the right financing partners to back the Company so that we could be fully positioned to grow. Secondly, … we have definitely been able to take the additional time that we've had since some foundational proof of concepts were created to further develop our algorithms, sharpen them up, and also use the results and develop them into excellent use cases that we can use as marketing collateral to go out and engage potential customers.” The discussion also highlights the Company's performance in 2021 and how its pivot into supply chains and smart manufacturing fits into future plans.

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Right on Brands, Inc. (OTC PINK: RTON), a fully reporting SEC filer and developer of a broad line of hemp-based smokables, beverages, tinctures, and topical products including products infused with CBD, Delta-8, Delta-10, THCV, CBDV, THC and Delta-9 (below the federal limit), to discuss the Company's cutting-edge products in the health and wellness space, the drivers behind the Company's success to date and goals for 2022. About ENDO Brands: ENDO Brands™, Humbly Hemp®, and ENDO Dispensary & Wellness™ All share the same goal of providing our customers with the best products in the health and wellness space. As the field of health and wellness products expand, Right on Brands will be there with industry-leading Food and Beverage and wellness Products. About Right on Brands: Right On Brands, Inc., (OTC Pink: RTON) is a Dallas based, consumer goods company specializing in the brand development and distribution of hemp-based foods, beverages, smokables, oils and topical products. To learn more, please visit: https://www.EndoBrands.com E-email Inquiries: info@endobrands.com Corporate Sales: Mike Brown (214) 736-7252 ENDO Brands Corporate Store: 6501 Dalrock Road Suite 100 Rowlett, Texas 75089 214-299-9528 Austin Licensed Location: 12412 Limerick Avenue (at the corner of Limerick and Parmer Lane_ Austin, Texas 75087 www.endoofaustin.com 512-621-0649

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with American Premium Water Corporation (OTC: HIPH) (the “Company”), a diversified luxury consumer products company focused on businesses in the health, beauty and biotech sectors to discuss the Company's recent news, the moves made in 2021 and the focus for 2022. American Premium Water (OTC: HIPH) is a diversified luxury consumer products company focused on businesses in the health, beauty and biotech sectors. The company is focused on harnessing the powers of Nano technologies paired without cannabidiol (CBD) to treat health disorders and enhance quality of life. The company's portfolio includes CaliBear (www.calibearlife.com) Vanexxe (www.vanexxe.com) plant + body essentials (www.plantbodyessentials.co). Shareholders and interested parties are encouraged to follow the Company's Twitter account @AmericanPremium and CEO Ryan Fishoff @RyanFishoff on Twitter for future Company updates, which will include material information about the Company.

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with The Singing Machine Company, Inc. (“Singing Machine” or the “Company”) (OTCQX: SMDM) – the worldwide leader in consumer karaoke products - to discuss the Company's stellar second quarter financial results, the moves made in 2021 and the focus for 2022. Speaking with SCV's Stuart Smith, Gary Atkinson, Singing Machine CEO, mentioned how home entertainment became vitally important in 2020 driving sales for the Company's consumer karaoke products in 2020. This strong demand developed through the global pandemic in 2020 continues to provide tailwinds for the company in 2021. He continued to note the other drivers behind the Company's strong revenues and net income for the second quarter ended September 30th, 2021. With a powerful distribution model already established with big-box retailers like Costco and e-commerce sites like Amazon, the Company can now focus on its growing subscription-based revenue model. Other highlights discussed in the interview include the successful completion of a $10 million private placement in August, the transformation of the shareholder base by bringing in a group of well-respected institutional funds, and the further development of the music subscription revenue model with strategic investor and partner, Stingray Group, Inc. In the interview, Atkinson stated, “The reason I'm so excited having Stingray be one our lead investors is they are a large technology and music content company. They have been our long-time partner and they power our digital karaoke content sales. The reason they made this investment in us, and the reason why this is potentially such a transformative event, is because they see us sell over a million karaoke units a year…the partnership with Stingray now allows for the music subscriptions sales and strengthens us to help build another recurring revenue model.” Atkinson continued, “One of the big things that we are working on right now is the up list process to a national exchange. We think that a listing on a national exchange will broaden the audience of the people that can transact in our stock. We are also working on bolstering our cash flow position, getting out inventory levels back in line, and really taking advantage of the demand that is out there.”

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT), to discuss the recently announced news that Mary Crowley Cancer Research center in Dallas, Texas is now actively screening and enrolling advanced breast cancer patients in the Phase I/IIa combination study of BriaCell's lead candidate, Bria-IMT™, with Incyte's checkpoint inhibitors, retifanlimab and epacadostat. “We are delighted to add Mary Crowley Cancer Research center with Dr. Barve as Principal Investigators to our team. Dr. Barve's leading knowledge and experience in biological therapies and immunotherapies for cancer will be highly valuable to us. We look forward to working with her team in our advanced breast cancer clinical trial to accelerate patient recruitment,” stated Dr. Williams, BriaCell's President and CEO. BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.

SmallCapVoice.com Inc. ("SCV") announces the availability of a new interview with Rhett Doolittle, CEO of Business Warrior Corp. (OTC:BZWR) ("the Company"), and Company President Jonathan Brooks to discuss Business Warrior's next-gen funding for small businesses. New lending service utilizes predictive technology to offer $5 million in loans to entrepreneurs. BZWR has partnered with elev8 Advisors Group to offer more than $5 million dollars in available loans to small business owners. The new lending solution leverages the expertise of both companies to help entrepreneurs grow their business and offset the difficulty often associated with receiving lending from a traditional bank. Business Warrior Corp. (OTC: BZWR) is the source for small businesses in America to enhance their brand and boost marketing results. The Business Warrior software takes a holistic view of a business' online reputation, listings, website search results and social media. Predictive algorithms are utilized to recommend the most imperative actions needed to drive new customers, positively impact daily operations and improve profitability. For more information, please visit www.BusinessWarrior.com.